Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view
The review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspir...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2007-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2207 |
| _version_ | 1797857206414082048 |
|---|---|
| author | D. A. Syche A. V. Zyatenkov B. G. Kukes |
| author_facet | D. A. Syche A. V. Zyatenkov B. G. Kukes |
| author_sort | D. A. Syche |
| collection | DOAJ |
| description | The review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspirin-resistant patients have significantly higher risk of thrombotic complications. Another widely used antiaggregant, clopidogrel, is ineffective in more than 15 % of the patients. Clopidogrel effectiveness depends on hepatic iso-enzyme CYP3A activity and ADP receptor gene variant. Many studies demonstrated that clopidogrel resistance worsens prognosis in coronary heart disease patients. Even new antiaggregants, Ilb-IIIa receptor inhibitors, are ineffective in 20 % of the cases, due to glycoprotein receptor gene polymorphism. Therefore, to identify optimal antiaggregant therapy regimen, individual approach is needed, including genetic and pharmacogenetic tests. |
| first_indexed | 2024-04-09T20:52:57Z |
| format | Article |
| id | doaj.art-3552757a9f944c68b8e4f4eb80aa18ce |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:52:57Z |
| publishDate | 2007-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-3552757a9f944c68b8e4f4eb80aa18ce2023-03-29T21:23:14Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202007-08-010491991959Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of viewD. A. Syche0A. V. Zyatenkov1B. G. Kukes2Московская медицинская академия им. И.М. СеченоваМосковская медицинская академия им. И.М. СеченоваИнститут клинической фармакологии НЦ ЭСМП РосздравнадзораThe review is devoted to individual antiaggregant sensitivity issue. According to numerous studies' data, acetylsalicylic acid is ineffective in 5 % of the patients. It might be explained by target molecule (COG-1) gene polymorphism. This phenomenon has important clinical implications, as aspirin-resistant patients have significantly higher risk of thrombotic complications. Another widely used antiaggregant, clopidogrel, is ineffective in more than 15 % of the patients. Clopidogrel effectiveness depends on hepatic iso-enzyme CYP3A activity and ADP receptor gene variant. Many studies demonstrated that clopidogrel resistance worsens prognosis in coronary heart disease patients. Even new antiaggregants, Ilb-IIIa receptor inhibitors, are ineffective in 20 % of the cases, due to glycoprotein receptor gene polymorphism. Therefore, to identify optimal antiaggregant therapy regimen, individual approach is needed, including genetic and pharmacogenetic tests.https://russjcardiol.elpub.ru/jour/article/view/2207pharmacogeneticsantiaggregantscoronary heart diseaseacetylsalicylic acidclopidogreliibfiiia receptor inhibitors |
| spellingShingle | D. A. Syche A. V. Zyatenkov B. G. Kukes Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view Российский кардиологический журнал pharmacogenetics antiaggregants coronary heart disease acetylsalicylic acid clopidogrel iibfiiia receptor inhibitors |
| title | Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view |
| title_full | Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view |
| title_fullStr | Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view |
| title_full_unstemmed | Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view |
| title_short | Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view |
| title_sort | clinical pharmacogenetics of antiaggregants clinical pharmacologist point of view |
| topic | pharmacogenetics antiaggregants coronary heart disease acetylsalicylic acid clopidogrel iibfiiia receptor inhibitors |
| url | https://russjcardiol.elpub.ru/jour/article/view/2207 |
| work_keys_str_mv | AT dasyche clinicalpharmacogeneticsofantiaggregantsclinicalpharmacologistpointofview AT avzyatenkov clinicalpharmacogeneticsofantiaggregantsclinicalpharmacologistpointofview AT bgkukes clinicalpharmacogeneticsofantiaggregantsclinicalpharmacologistpointofview |